Our funding and expenditure

MMV receives sustained funding and support from government agencies, private foundations, international organizations, corporations, corporate foundations and private individuals. These funds are used to finance MMV’s portfolio of R&D projects as well as specific, targeted access and delivery interventions that aim to make it easier for vulnerable populations to access MMV products.

Since its foundation in 1999, MMV has spent USD 709 million to build the world’s largest R&D portfolio of new and innovative antimalarial medicines. With partners, MMV has brought forward six new antimalarials and distributed millions of treatments that are saving lives. Our business plan estimates needing a minimum of USD 430 million over the period 2017–2021 to sustain this work.

Progress in research is dependent on funding. With approximately USD 230 million available, (USD 185 million outstanding committed pledges for 2017–2021 at the end of 2016, as well as USD 45 million cash brought forward to 2017), the organization is currently tracking a shortfall of USD 200 million for 2018-2021. To overcome this, MMV is striving to expand and develop current and new donors and negotiate the best terms with our partners.

Total funding received/pledged from 1999 to 2020 

USD 893 million as at 31 December 2015

MMV expenditure 2015 – Total: USD 80.6 million

MMV income and expenditure to date and scenario 2016–2020

More details are available in the Financial Section of our Annual Report.

 


 

Updated June 2016